{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:47:24Z","timestamp":1790297244722,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Amsterdam Research Priority Agenda Program AI for Health Decision-Making"},{"DOI":"10.13039\/100019741","name":"Amsterdam Cardiovascular Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019741","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) exhibit structural and functional cardiac abnormalities. We aimed to identify imaging biomarkers for pre-clinical cardiomyopathy in healthy participants carrying cardiomyopathy-associated variants (G\u2009+).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included 40,169 UK Biobank participants free of\u00a0cardiac disease at the time of cardiac magnetic resonance imaging (CMR) and with\u00a0whole exome sequencing. We validated 22 CMR measurements by associating them with incident atrial fibrillation (AF) or heart failure (HF). We subsequently assessed associations of these CMR\u00a0measurements with HCM G+, DCM G\u2009+\u2009, or specific genes, utilising generalised linear models conditional on cardiac risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirteen CMR measurements were associated with incident AF and 15 with HF. These included left ventricular (LV) ejection fraction (EF; hazard ratio [HR] 0.61, 95% confidence interval [95%CI] 0.54; 0.69) for HF and indexed maximum left atrial volume (LAVi max; HR 1.47, 95%CI 1.29; 1.67) for AF. Five measurements associated with HCM G\u2009+\u2009, amongst which right ventricular (RV) end-systolic volume (RV-ESV; odds ratio [OR] 0.62, 95%CI 0.53; 0.74), RV-EF (OR 1.36, 95%CI 1.19; 1.55), and right atrial (RA)\u00a0EF (OR 1.22, 95%CI 1.08; 1.39). Associations overlapping with incident disease and HCM G\u2009+\u2009had opposite effect directions, such as RV-ESV with HF (HR 1.22, 95%CI 1.07; 1.40). Two CMR measurements associated with DCM G\u2009+\u2009: LV-ESVi (OR 1.35, 95%CI 1.15; 1.58) and LV-EF (OR 0.75, 95%CI 0.64; 0.88). We observed significant associations with individual cardiomyopathy genes, finding that\u00a0mitral annular plane systolic excursion associated with\n                      <jats:italic>TTN<\/jats:italic>\n                      and\n                      <jats:italic>TNNT2<\/jats:italic>\n                      , and LA pump volume and RA-EF associated with\n                      <jats:italic>MYH7<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified right-heart CMR measurements associated with HCM G\u2009+\u2009in healthy individuals, indicating early compensation of cardiac function. LV measurements associated with DCM G\u2009+\u2009, where CMR associations varied across individual DCM genes, suggesting distinct early pathophysiology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-025-04226-4","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:14:04Z","timestamp":1752538444000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cardiac magnetic resonance markers of pre-clinical hypertrophic and dilated cardiomyopathy in genetic variant carriers"],"prefix":"10.1186","volume":"23","author":[{"given":"Philip M.","family":"Croon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis P.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Ruijsink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry M.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Asselbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Khera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie R.","family":"Bezzina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Floriaan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"4226_CR1","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, et al. 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J. 2023;44. Available from: https:\/\/academic.oup.com\/eurheartj\/article-abstract\/44\/37\/3503\/7246608."},{"key":"4226_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.116.001620","volume":"10","author":"J Ingles","year":"2017","unstructured":"Ingles J, Burns C, Bagnall RD, Lam L, Yeates L, Sarina T, Puranik R, Briffa T, Atherton JJ, Driscoll T, et al. Nonfamilial hypertrophic cardiomyopathy: prevalence, natural history, and clinical implications. Circ Cardiovasc Genet. 2017;10: e001620.","journal-title":"Circ Cardiovasc Genet"},{"key":"4226_CR3","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1097\/GIM.0b013e3181f2481f","volume":"12","author":"RE Hershberger","year":"2010","unstructured":"Hershberger RE, Morales A, Siegfried JD. Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals. Genet Med. 2010;12:655\u201367.","journal-title":"Genet Med"},{"key":"4226_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrcardio.2013.105","volume":"10","author":"RE Hershberger","year":"2013","unstructured":"Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531\u201347.","journal-title":"Nat Rev Cardiol"},{"key":"4226_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0735-1097(97)00434-8","volume":"31","author":"E Gr\u00fcnig","year":"1998","unstructured":"Gr\u00fcnig E, Tasman JA, K\u00fccherer H, Franz W, K\u00fcbler W, Katus HA. Frequency and phenotypes of familial dilated cardiomyopathy. J Am Coll Cardiol. 1998;31:186\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"4226_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.amjcard.2011.06.022","volume":"108","author":"M Petretta","year":"2011","unstructured":"Petretta M, Pirozzi F, Sasso L, Paglia A, Bonaduce D. Review and metaanalysis of the frequency of familial dilated cardiomyopathy. Am J Cardiol. 2011;108:1171\u20136.","journal-title":"Am J Cardiol"},{"key":"4226_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003704","volume":"15","author":"M Bourfiss","year":"2022","unstructured":"Bourfiss M, van Vugt M, Alasiri AI, Ruijsink B, van Setten J, Schmidt AF, Dooijes D, Puyol-Ant\u00f3n E, Velthuis BK, van Tintelen JP, et al. Prevalence and disease expression of pathogenic and likely pathogenic variants associated with inherited cardiomyopathies in the general population. Circ Genomic Precis Med. 2022;15: e003704.","journal-title":"Circ Genomic Precis Med"},{"key":"4226_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.122.003716","volume":"16","author":"N Aung","year":"2023","unstructured":"Aung N, Lopes LR, van Duijvenboden S, Harper AR, Goel A, Grace C, Ho CY, Weintraub WS, Kramer CM, Neubauer S, et al. Genome-wide analysis of left ventricular maximum wall thickness in the UK Biobank cohort reveals a shared genetic background with hypertrophic cardiomyopathy. Circ Genomic Precis Med. 2023;16: e003716.","journal-title":"Circ Genomic Precis Med"},{"key":"4226_CR9","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/s41467-020-15823-7","volume":"11","author":"JP Pirruccello","year":"2020","unstructured":"Pirruccello JP, Bick A, Wang M, Chaffin M, Friedman S, Yao J, Guo X, Venkatesh BA, Taylor KD, Post WS, et al. Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nat Commun. 2020;11:2254.","journal-title":"Nat Commun"},{"key":"4226_CR10","doi-asserted-by":"publisher","first-page":"eadd4984","DOI":"10.1126\/sciadv.add4984","volume":"9","author":"AF Schmidt","year":"2023","unstructured":"Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, van der Laan SW, Gross C, Clarkson C, Henry A, et al. Druggable proteins influencing cardiac structure and function: implications for heart failure therapies and cancer cardiotoxicity. Sci Adv. 2023;9:eadd4984.","journal-title":"Sci Adv."},{"key":"4226_CR11","first-page":"684","volume":"13","author":"B Ruijsink","year":"2020","unstructured":"Ruijsink B, Puyol-Ant\u00f3n E, Oksuz I, Sinclair M, Bai W, Schnabel JA, Razavi R, King AP. Fully automated, quality-controlled cardiac analysis from CMR: validation and large-scale application to characterize cardiac function. Cardiovasc Imaging. 2020;13:684\u201395.","journal-title":"Cardiovasc Imaging"},{"key":"4226_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.ajhg.2017.04.015","volume":"100","author":"NT Strande","year":"2017","unstructured":"Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, DiStefano M, Dwight SS, Goldstein J, Ghosh R, Seifert BA, Sneddon TP, et al. Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the clinical genome resource. Am J Hum Genet. 2017;100:895\u2013906.","journal-title":"Am J Hum Genet"},{"key":"4226_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.119.002460","volume":"12","author":"J Ingles","year":"2019","unstructured":"Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dougherty K, Harrison SM, McGlaughon J, Milko LV, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genomic Precis Med. 2019;12: e002460.","journal-title":"Circ Genomic Precis Med"},{"key":"4226_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.120.053033","volume":"144","author":"E Jordan","year":"2021","unstructured":"Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E, Celeghin R, Edwards M, Fan J, Ingles J, et al. Evidence-based assessment of genes in dilated cardiomyopathy. Circulation. 2021;144:7\u201319.","journal-title":"Circulation"},{"key":"4226_CR15","first-page":"1","volume":"18","author":"SE Petersen","year":"2015","unstructured":"Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, Young AA, Hudson S, Weale P, Garratt S, et al. UK Biobank\u2019s cardiovascular magnetic resonance protocol. J Cardiovasc Magn Reson. 2015;18:1\u20137.","journal-title":"J Cardiovasc Magn Reson"},{"key":"4226_CR16","doi-asserted-by":"publisher","first-page":"D977","DOI":"10.1093\/nar\/gkac1010","volume":"51","author":"E Sollis","year":"2023","unstructured":"Sollis E, Mosaku A, Abid A, Buniello A, Cerezo M, Gil L, Groza T, G\u00fcne\u015f O, Hall P, Hayhurst J, et al. The NHGRI-EBI GWAS Catalog: knowledgebase and deposition resource. Nucleic Acids Res. 2023;51:D977\u201385.","journal-title":"Nucleic Acids Res"},{"key":"4226_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.119.002804","volume":"13","author":"H Choquet","year":"2020","unstructured":"Choquet H, Thai KK, Jiang C, Ranatunga DK, Hoffmann TJ, Go AS, Lindsay AC, Ehm MG, Waterworth DM, Risch N, et al. Meta-analysis of 26 638 individuals identifies two genetic loci associated with left ventricular ejection fraction. Circ Genomic Precis Med. 2020;13: e002804.","journal-title":"Circ Genomic Precis Med"},{"key":"4226_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","volume":"53","author":"R Tadros","year":"2021","unstructured":"Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, Kelu Bisabu K, Walsh R, Hoorntje ET, te Rijdt WP, et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat Genet. 2021;53:128\u201334.","journal-title":"Nat Genet"},{"key":"4226_CR19","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/ejhf.2482","volume":"24","author":"IS Forrest","year":"2022","unstructured":"Forrest IS, Rocheleau G, Bafna S, Argulian E, Narula J, Natarajan P, Do R. Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure. Eur J Heart Fail. 2022;24:2118\u201327.","journal-title":"Eur J Heart Fail"},{"key":"4226_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.echo.2015.07.015","volume":"28","author":"M Ro\u015fca","year":"2015","unstructured":"Ro\u015fca M, C\u0103lin A, Beladan CC, Enache R, Mateescu AD, Gurzun M-M, Varga P, B\u0103icu\u015f C, Coman IM, Jurcu\u0163 R, et al. Right ventricular remodeling, its correlates, and its clinical impact in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2015;28:1329\u201338.","journal-title":"J Am Soc Echocardiogr"},{"key":"4226_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12968-022-00868-y","volume":"24","author":"M Mahmod","year":"2022","unstructured":"Mahmod M, Raman B, Chan K, Sivalokanathan S, Smillie RW, Abd Samat AH, Ariga R, Dass S, Ormondroyd E, Watkins H, et al. Right ventricular function declines prior to left ventricular ejection fraction in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2022;24:36.","journal-title":"J Cardiovasc Magn Reson"},{"key":"4226_CR22","doi-asserted-by":"crossref","unstructured":"Gandjbakhch E, Gackowski A, Tezenas du Montcel S, Isnard R, Hamroun A, Richard P, Komajda M, Charron P. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. Eur Heart J. 2010;31:1599\u20131607.","DOI":"10.1093\/eurheartj\/ehq101"},{"key":"4226_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1161\/CIRCGENETICS.109.862128","volume":"2","author":"CY Ho","year":"2009","unstructured":"Ho CY, Carlsen C, Thune JJ, Havndrup O, Bundgaard H, Farrohi F, Rivero J, Cirino AL, Andersen PS, Christiansen M, et al. Echocardiographic strain imaging to assess early and late consequences of sarcomere mutations in hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2009;2:314\u201321.","journal-title":"Circ Cardiovasc Genet"},{"key":"4226_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamacardio.2016.5670","volume":"2","author":"CY Ho","year":"2017","unstructured":"Ho CY, Day SM, Colan SD, Russell MW, Towbin JA, Sherrid MV, Canter CE, Jefferies JL, Murphy AM, Cirino AL, et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: findings from the HCMNet study. JAMA Cardiol. 2017;2:419\u201328.","journal-title":"JAMA Cardiol"},{"key":"4226_CR25","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1161\/CIRCULATIONAHA.108.838672","volume":"119","author":"SJ Van Dijk","year":"2009","unstructured":"Van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, ten Cate FJ, Stienen GJ, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation. 2009;119:1473\u201383.","journal-title":"Circulation"},{"key":"4226_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0180064","volume":"12","author":"JW McNamara","year":"2017","unstructured":"McNamara JW, Li A, Lal S, Bos JM, Harris SP, Van Der Velden J, Ackerman MJ, Cooke R, Dos Remedios CG. MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy. PLoS ONE. 2017;12: e0180064.","journal-title":"PLoS ONE"},{"key":"4226_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/14017431.2021.1901979","volume":"55","author":"SG Berger","year":"2021","unstructured":"Berger SG, Sjaastad I, Stokke MK. Right ventricular involvement in hypertrophic cardiomyopathy: evidence and implications from current literature. Scand Cardiovasc J. 2021;55:195\u2013204.","journal-title":"Scand Cardiovasc J"},{"key":"4226_CR28","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","volume":"83","author":"SR Ommen","year":"2024","unstructured":"Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, Day SM, Dearani JA, Epps KC, Evanovich L, Ferrari VA, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83:2324\u2013405.","journal-title":"J Am Coll Cardiol"},{"key":"4226_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hjc.2018.11.009","volume":"61","author":"K Keramida","year":"2020","unstructured":"Keramida K, Lazaros G, Nihoyannopoulos P. Right ventricular involvement in hypertrophic cardiomyopathy: patterns and implications. Hellenic J Cardiol. 2020;61:3\u20138.","journal-title":"Hellenic J Cardiol"},{"key":"4226_CR30","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s41598-020-58775-0","volume":"10","author":"X Li","year":"2020","unstructured":"Li X, Shi K, Yang Z, Guo Y, Huang S, Xia C, He S, Li Z, Li C, He Y. Assessing right ventricular deformation in hypertrophic cardiomyopathy patients with preserved right ventricular ejection fraction: a 3.0-T cardiovascular magnetic resonance study. Sci Rep. 2020;10:1967.","journal-title":"Sci Rep."},{"key":"4226_CR31","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1093\/eurheartj\/ehad510","volume":"44","author":"DC Benz","year":"2023","unstructured":"Benz DC, Gr\u00e4ni C, Antiochos P, Heydari B, Gissler MC, Ge Y, Cuddy SA, Dorbala S, Kwong RY. Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases. Eur Heart J. 2023;44:4738\u201347.","journal-title":"Eur Heart J"},{"key":"4226_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007840","volume":"14","author":"M Guazzi","year":"2021","unstructured":"Guazzi M, Naeije R. Right heart phenotype in heart failure with preserved ejection fraction. Circ Heart Fail. 2021;14: e007840.","journal-title":"Circ Heart Fail"},{"key":"4226_CR33","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","volume":"73","author":"J Sanz","year":"2019","unstructured":"Sanz J, S\u00e1nchez-Quintana D, Bossone E, Bogaard HJ, Naeije R. Anatomy, function, and dysfunction of the right ventricle: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73:1463\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"4226_CR34","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jacc.2023.05.010","volume":"82","author":"RM Inciardi","year":"2023","unstructured":"Inciardi RM, Abanda M, Shah AM, Cikes M, Claggett B, Skali H, Vaduganathan M, Prasad N, Litwin S, Merkely B, et al. Right ventricular function and pulmonary coupling in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2023;82:489\u201399.","journal-title":"J Am Coll Cardiol"},{"key":"4226_CR35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016;351:617\u201321.","journal-title":"Science"},{"key":"4226_CR36","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jcmg.2018.03.006","volume":"11","author":"MA Becker","year":"2018","unstructured":"Becker MA, Cornel JH, Van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging. 2018;11:1274\u201384.","journal-title":"JACC Cardiovasc Imaging"},{"key":"4226_CR37","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaa5458","volume":"349","author":"JT Hinson","year":"2015","unstructured":"Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, Gorham J, Yang L, Schafer S, Sheng CC, et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349:982\u20136.","journal-title":"Science"},{"key":"4226_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1172\/JCI62862","volume":"123","author":"EM McNally","year":"2013","unstructured":"McNally EM, Golbus JR, Puckelwartz MJ, et al. Genetic mutations and mechanisms in dilated cardiomyopathy. J Clin Invest. 2013;123:19\u201326.","journal-title":"J Clin Invest."},{"key":"4226_CR39","doi-asserted-by":"crossref","unstructured":"Coppini R, Ho CY, Ashley E, Day S, Ferrantini C, Girolami F, Tomberli B, Bardi S, Torricelli F, Cecchi F, et al. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J Am Coll Cardiol. 2014;64. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4270453\/.","DOI":"10.1016\/j.jacc.2014.09.059"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-04226-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-04226-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T09:42:58Z","timestamp":1757238178000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-04226-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-04226-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.11.15.24317368","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the UKB study was obtained from the North West Centre for Research Ethics Committee (11\/NW\/0382) and all participants provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication is not required, because no details on individuals are reported within the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AFS has received funding from New Amsterdam Pharma for unrelated projects. PMC is founder, CEO and shareholder of DGTL Health B.V. FWA is supported by UCL Hospitals NIHR Biomedical Research Centre. RK is an Associate Editor of JAMA. He receives support from the National Heart, Lung, and Blood Institute of the National Institutes of Health (under awards R01HL167858 and K23HL153775), the Doris Duke Charitable Foundation (under award 2022060), and the Blavatnik Family Foundation. He also receives research support, through Yale, from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Pending Patent Applications 63\/562,335, 63\/177,117, 63\/428,569, 63\/346,610, 63\/484,426, 63\/508,315, and 63\/606,203. He is a co-founder of Ensight-AI, Inc. and Evidence2Health, health platforms to improve cardiovascular diagnosis and evidence-based cardiovascular care.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"421"}}